Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study

美波利祖马布 苯拉唑马布 医学 哮喘 肺功能 观察研究 嗜酸性 回顾性队列研究 内科学 嗜酸性粒细胞 肺 病理
作者
Shoko Isoyama,Nobuhisa Ishikawa,Kosuke Hamai,Mirai Matsumura,Hiroki Kobayashi,Akio Nomura,Sayaka Ueno,Takuya Tanimoto,Hiroyuki Maeda,Hiroshi Iwamoto,Noboru Hattori
出处
期刊:Internal Medicine [The Japanese Society of Internal Medicine]
卷期号:61 (11): 1663-1671 被引量:6
标识
DOI:10.2169/internalmedicine.8180-21
摘要

Objective Switching from mepolizumab to benralizumab has been reported to significantly improve both asthma control and the lung function. However, the data on its efficacy in elderly patients with severe eosinophilic asthma are limited. This study aimed to assess whether elderly patients with severe eosinophilic asthma could experience an improved asthma control and lung function when switching directly from mepolizumab to benralizumab. Methods In this single-center, retrospective study conducted between February 2017 and September 2018, we assessed the effect of switching the treatment directly from mepolizumab to benralizumab on eosinophil levels, exacerbation rates, and lung function. We compared the treatment responses between the two groups using either Fisher's exact test or Mann-Whitney U-test, as appropriate. Patients We enrolled 12 elderly patients (age ≥65 years) with severe eosinophilic asthma treated with mepolizumab at Hiroshima Prefectural Hospital (Hiroshima, Japan) during the study period. Six patients were switched from mepolizumab to benralizumab, and six continued with the mepolizumab treatment. Results The switch from mepolizumab to benralizumab caused a near-complete reduction in the eosinophil count (p=0.008). The annual rate of clinically relevant exacerbations and hospitalizations diminished as well, albeit with no statistical significance. We found no improvement in the lung function after switching treatment and no difference in the treatment response between the groups. Conclusion Although this study is based on a small sample of participants, the results indicate that both mepolizumab treatment and switching from mepolizumab to benralizumab treatment without a washout period have clinically relevant asthma control benefits for elderly patients with severe eosinophilic asthma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈妮s发布了新的文献求助10
刚刚
wanci的应助被Layman采纳,获得10
刚刚
终极老中医完成签到,获得积分10
刚刚
科研通AI6.3的应助被tlc_191026采纳,获得10
2秒前
3秒前
高权喜完成签到,获得积分10
3秒前
4秒前
Frank发布了新的文献求助10
4秒前
英俊的铭的应助被好命姐采纳,获得10
4秒前
丘比特的应助被牧百川采纳,获得10
4秒前
5秒前
南海子完成签到,获得积分10
6秒前
秀秀发布了新的文献求助10
7秒前
8秒前
郑睿涛发布了新的文献求助10
9秒前
9秒前
LingC完成签到,获得积分10
9秒前
FiiisH发布了新的文献求助10
10秒前
今后的应助被小涵采纳,获得10
10秒前
chance完成签到,获得积分10
10秒前
yjw0526完成签到,获得积分10
10秒前
ZL对应助文件撤销了驳回
11秒前
小马甲的应助被renn采纳,获得20
11秒前
12秒前
开心枣枣完成签到 ,获得积分10
12秒前
13秒前
15秒前
科目三的应助被MiyaGuo采纳,获得10
15秒前
哈妮s完成签到,获得积分10
15秒前
Dreamer发布了新的文献求助10
15秒前
科研通AI6.2的应助被Frank采纳,获得10
15秒前
热情松鼠完成签到,获得积分20
16秒前
17秒前
辛勤怜寒完成签到 ,获得积分10
18秒前
hzzzzz发布了新的文献求助10
18秒前
19秒前
友好的冰巧完成签到,获得积分10
20秒前
20秒前
lmy的应助被xxdwyd采纳,获得10
21秒前
科研通AI6.3的应助被tlc_191026采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183508
求助须知:如何正确求助?哪些是违规求助? 9572862
关于积分的说明 21827639
捐赠科研通 7780681
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480405